SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/20/25
SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCLGlobeNewsWire • 02/20/25
SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 01/28/25
SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid LeukemiaGlobeNewsWire • 01/23/25
SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid LeukemiaGlobeNewsWire • 12/10/24
SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AMLGlobeNewsWire • 12/09/24
SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid CancersGlobeNewsWire • 11/27/24
SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/13/24
voxeljet, Dressler Group GmbH, Fraunhofer IPA and the University of Bayreuth Collaborate in Re-Processing of Discarded PA12 Powder for 3D Printing via High-Speed Sintering (HSS)Business Wire • 11/13/24
SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024GlobeNewsWire • 11/05/24
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid LeukemiaGlobeNewsWire • 10/15/24
SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual SummitGlobeNewsWire • 10/10/24
SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/13/24
SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell LymphomasGlobeNewsWire • 08/06/24
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid LeukemiaGlobeNewsWire • 07/16/24
SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid LeukemiaGlobeNewsWire • 07/08/24
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic LeukemiaGlobeNewsWire • 06/24/24
SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid LeukemiaGlobeNewsWire • 06/17/24
SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AMLGlobeNewsWire • 06/10/24
Galena Biopharma (SLS) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 05/20/24
SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/14/24
SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose LevelGlobeNewsWire • 05/01/24
SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 StudyGlobeNewsWire • 04/29/24